Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Ukraiński (UK)
Przejdź do strony domowej biblioteki Uniwersytet Ekonomiczny we Wrocławiu Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaUniwersytet Ekonomiczny we Wrocławiu

Wyszukujesz frazę ""TENOFOVIR"" wg kryterium: Temat

  Lista filtrów
Wyrównaj
Wyświetlanie 1-20 z 13372
Tytuł:
Adherence and HIV Protection Thresholds for Emtricitabine and Tenofovir Disoproxil Fumarate Preexposure Prophylaxis among Cisgender Women: A Systematic Review.
Autorzy:
Wu L; Department of Global Health, University of Washington, 908 Jefferson Street, Seattle, WA, 98104, USA.; Department of Epidemiology, University of Washington, 3980 15th Ave NE, Seattle, WA, 98195, USA.
Niu X; Department of Global Health, University of Washington, 908 Jefferson Street, Seattle, WA, 98104, USA.; Department of Epidemiology, University of Washington, 3980 15th Ave NE, Seattle, WA, 98195, USA.
Brunelli MK; School of Public Health, University of Washington, Seattle, WA, USA.
Mugwanya KK; Department of Global Health, University of Washington, 908 Jefferson Street, Seattle, WA, 98104, USA. .; Department of Epidemiology, University of Washington, 3980 15th Ave NE, Seattle, WA, 98195, USA. .
Pokaż więcej
Źródło:
Current HIV/AIDS reports [Curr HIV/AIDS Rep] 2024 Oct; Vol. 21 (5), pp. 264-281. Date of Electronic Publication: 2024 Aug 09.
Typ publikacji:
Systematic Review; Journal Article; Review
MeSH Terms:
Pre-Exposure Prophylaxis*/methods
HIV Infections*/prevention & control
HIV Infections*/drug therapy
Anti-HIV Agents*/therapeutic use
Anti-HIV Agents*/administration & dosage
Medication Adherence*/statistics & numerical data
Tenofovir*/therapeutic use
Tenofovir*/administration & dosage
Humans ; Female ; Emtricitabine/therapeutic use ; Emtricitabine/administration & dosage ; Pregnancy ; Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination/therapeutic use ; Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination/administration & dosage ; Leukocytes, Mononuclear ; Adenine/analogs & derivatives ; Organophosphates
Czasopismo naukowe
Full Text Finder  Link otwiera się w nowym oknieSzczegóły
Tytuł:
No observed bidirectional effect between tenofovir diphosphate concentrations and gender-affirming hormone concentrations among transgender persons switching from tenofovir disoproxil fumarate/emtricitabine to tenofovir alafenamide/emtricitabine for HIV pre-exposure prophylaxis.
Autorzy:
Patel N; Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, La Jolla, California, USA.
Morris S; School of Medicine, University of California San Diego, La Jolla, California, USA.; AntiViral Research Center, University of California San Diego, La Jolla, California, USA.
Burke L; AntiViral Research Center, University of California San Diego, La Jolla, California, USA.
Chow K; AntiViral Research Center, University of California San Diego, La Jolla, California, USA.
Pacheco D; AntiViral Research Center, University of California San Diego, La Jolla, California, USA.
Anderson P; Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.
Stancyzk F; University of Southern California, Los Angeles, California, USA.
Blumenthal J; School of Medicine, University of California San Diego, La Jolla, California, USA.; AntiViral Research Center, University of California San Diego, La Jolla, California, USA.
Pokaż więcej
Źródło:
British journal of clinical pharmacology [Br J Clin Pharmacol] 2024 Oct; Vol. 90 (10), pp. 2360-2365. Date of Electronic Publication: 2024 Apr 22.
Typ publikacji:
Journal Article
MeSH Terms:
Transgender Persons*
Tenofovir*/administration & dosage
Tenofovir*/analogs & derivatives
HIV Infections*/prevention & control
Pre-Exposure Prophylaxis*/methods
Anti-HIV Agents*/administration & dosage
Anti-HIV Agents*/pharmacokinetics
Adenine*/analogs & derivatives
Adenine*/administration & dosage
Adenine*/therapeutic use
Adenine*/pharmacokinetics
Adenine*/blood
Humans ; Male ; Adult ; Female ; Middle Aged ; Emtricitabine/administration & dosage ; Alanine/administration & dosage ; Alanine/blood ; Drug Substitution ; Drug Combinations ; Young Adult ; Organophosphates/administration & dosage ; Organophosphates/blood ; Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination/administration & dosage ; Phosphorous Acids/administration & dosage
Czasopismo naukowe
Full Text Finder  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Profiling the Interaction between Human Serum Albumin and Clinically Relevant HIV Reverse Transcriptase Inhibitors.
Autorzy:
Costa-Tuna A; CQC-IMS, Department of Chemistry, University of Coimbra, Rua Larga, 3004-535 Coimbra, Portugal.
Chaves OA; CQC-IMS, Department of Chemistry, University of Coimbra, Rua Larga, 3004-535 Coimbra, Portugal.; Laboratory of Immunopharmacology, Centro de Pesquisa, Inovação e Vigilância em COVID-19 e Emergências Sanitárias (CPIV), Oswaldo Cruz Institute (IOC), Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro 21040-361, RJ, Brazil.
Almeida ZL; CQC-IMS, Department of Chemistry, University of Coimbra, Rua Larga, 3004-535 Coimbra, Portugal.
Cunha RS; CQC-IMS, Department of Chemistry, University of Coimbra, Rua Larga, 3004-535 Coimbra, Portugal.
Pina J; CQC-IMS, Department of Chemistry, University of Coimbra, Rua Larga, 3004-535 Coimbra, Portugal.
Serpa C; CQC-IMS, Department of Chemistry, University of Coimbra, Rua Larga, 3004-535 Coimbra, Portugal.
Pokaż więcej
Źródło:
Viruses [Viruses] 2024 Mar 22; Vol. 16 (4). Date of Electronic Publication: 2024 Mar 22.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Tenofovir*/*analogs & derivatives
Reverse Transcriptase Inhibitors*/metabolism
Reverse Transcriptase Inhibitors*/chemistry
Tenofovir*/metabolism
Tenofovir*/chemistry
Serum Albumin, Human*/metabolism
Serum Albumin, Human*/chemistry
Protein Binding*
Anti-HIV Agents*/metabolism
Humans ; Thermodynamics ; Calorimetry ; Binding Sites ; HIV Infections/virology ; HIV Infections/drug therapy ; Alanine/metabolism ; HIV Reverse Transcriptase/metabolism ; HIV Reverse Transcriptase/chemistry
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Risk of dyslipidaemia in people living with HIV who are taking tenofovir alafenamide: a systematic review and meta-analysis.
Autorzy:
Yoo JJ; Department of Internal Medicine, Soonchunhyang University Bucheon Hospital, Soonchunhyang University College of Medicine, Bucheon, Republic of Korea.
Jung EA; Department of Medical Library, Soonchunhyang University Bucheon Hospital, Soonchunhyang University College of Medicine, Bucheon, Republic of Korea.
Kim SG; Department of Internal Medicine, Soonchunhyang University Bucheon Hospital, Soonchunhyang University College of Medicine, Bucheon, Republic of Korea.
Kim YS; Department of Internal Medicine, Soonchunhyang University Bucheon Hospital, Soonchunhyang University College of Medicine, Bucheon, Republic of Korea.
Kim MJ; Department of Infectious Diseases, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
Pokaż więcej
Źródło:
Journal of the International AIDS Society [J Int AIDS Soc] 2024 Sep; Vol. 27 (9), pp. e26358.
Typ publikacji:
Journal Article; Systematic Review; Meta-Analysis
MeSH Terms:
HIV Infections*/drug therapy
Tenofovir*/therapeutic use
Tenofovir*/adverse effects
Tenofovir*/analogs & derivatives
Anti-HIV Agents*/therapeutic use
Anti-HIV Agents*/adverse effects
Dyslipidemias*/chemically induced
Humans ; Alanine/therapeutic use ; Risk Factors ; Male ; Aminobutyrates/adverse effects ; Aminobutyrates/therapeutic use ; Female ; Adenine/analogs & derivatives ; Adenine/therapeutic use ; Adenine/adverse effects
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in virologically suppressed patient with chronic hepatitis B.
Autorzy:
Nam H; The Catholic University Liver Research Center, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.; Division of Hepatology, Department of Internal Medicine, Uijeongbu St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Bucheon-si, Republic of Korea.
Han JW; The Catholic University Liver Research Center, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.; Division of Hepatology, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
Lee SK; The Catholic University Liver Research Center, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.; Division of Hepatology, Department of Internal Medicine, Incheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Incheon, Republic of Korea.
Yang H; The Catholic University Liver Research Center, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.; Division of Hepatology, Department of Internal Medicine, Eunpyeong St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
Lee HL; The Catholic University Liver Research Center, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.; Division of Hepatology, Department of Internal Medicine, Bucheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Bucheon-si, Republic of Korea.
Sung PS; The Catholic University Liver Research Center, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.; Division of Hepatology, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
Song MJ; The Catholic University Liver Research Center, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.; Division of Hepatology, Department of Internal Medicine, Daejeon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Daejeon, Republic of Korea.
Kwon JH; The Catholic University Liver Research Center, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.; Division of Hepatology, Department of Internal Medicine, Incheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Incheon, Republic of Korea.
Jang JW; The Catholic University Liver Research Center, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.; Division of Hepatology, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
Chang UI; The Catholic University Liver Research Center, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.; Division of Hepatology, Department of Internal Medicine, St. Vincent's Hospital, College of Medicine, The Catholic University of Korea, Bucheon-si, Republic of Korea.
Kim CW; The Catholic University Liver Research Center, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.; Division of Hepatology, Department of Internal Medicine, Uijeongbu St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Bucheon-si, Republic of Korea.
Nam SW; The Catholic University Liver Research Center, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.; Division of Hepatology, Department of Internal Medicine, Incheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Incheon, Republic of Korea.
Bae SH; The Catholic University Liver Research Center, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.; Division of Hepatology, Department of Internal Medicine, Eunpyeong St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
Choi JY; The Catholic University Liver Research Center, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.; Division of Hepatology, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
Yoon SK; The Catholic University Liver Research Center, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.; Division of Hepatology, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
Yang JM; The Catholic University Liver Research Center, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.; Division of Hepatology, Department of Internal Medicine, St. Vincent's Hospital, College of Medicine, The Catholic University of Korea, Bucheon-si, Republic of Korea.
Kim HY; The Catholic University Liver Research Center, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.; Division of Hepatology, Department of Internal Medicine, Bucheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Bucheon-si, Republic of Korea.
Pokaż więcej
Źródło:
Journal of gastroenterology and hepatology [J Gastroenterol Hepatol] 2024 Aug; Vol. 39 (8), pp. 1673-1683. Date of Electronic Publication: 2024 May 01.
Typ publikacji:
Journal Article; Multicenter Study
MeSH Terms:
Tenofovir*/therapeutic use
Tenofovir*/administration & dosage
Tenofovir*/adverse effects
Tenofovir*/analogs & derivatives
Hepatitis B, Chronic*/drug therapy
Glomerular Filtration Rate*/drug effects
Drug Substitution*
Bone Density*/drug effects
Alanine*/therapeutic use
Antiviral Agents*/administration & dosage
Antiviral Agents*/adverse effects
Humans ; Male ; Middle Aged ; Female ; Retrospective Studies ; Treatment Outcome ; Adenine/analogs & derivatives ; Adenine/therapeutic use ; Adenine/adverse effects ; Adenine/administration & dosage ; Aged ; Adult
Czasopismo naukowe
Full Text Finder  Link otwiera się w nowym oknieSzczegóły
Tytuł:
A systematic review and meta-analysis of the risk of hepatitis B virus (HBV) resistance in people treated with entecavir or tenofovir.
Autorzy:
Lumley SF; Nuffield Department of Medicine, University of Oxford, Oxford, UK; Department of Infectious Diseases and Microbiology, Oxford University Hospitals NHS Foundation Trust, UK. Electronic address: .
Delphin M; The Francis Crick Institute, 1 Midland Road, London, UK.
Mokaya JF; Parasites and Microbes, Wellcome Sanger Institute, Hinxton, UK.
Tan CCS; The Francis Crick Institute, 1 Midland Road, London, UK.
Martyn E; The Francis Crick Institute, 1 Midland Road, London, UK.
Anderson M; The Francis Crick Institute, 1 Midland Road, London, UK; Africa Health Research Institute, Durban, SA.
Li KC; The Francis Crick Institute, 1 Midland Road, London, UK.
Waddilove E; The Francis Crick Institute, 1 Midland Road, London, UK.
Sukali G; University of KwaZulu Natal, Nelson R Mandela Medical School,Durban, SA.
Downs LO; Nuffield Department of Medicine, University of Oxford, Oxford, UK; Department of Infectious Diseases and Microbiology, Oxford University Hospitals NHS Foundation Trust, UK; KEMRI-Wellcome Trust, Kilifi, Kenya.
Said K; The Francis Crick Institute, 1 Midland Road, London, UK.
Okanda D; KEMRI-Wellcome Trust, Kilifi, Kenya.
Campbell C; Nuffield Department of Medicine, University of Oxford, Oxford, UK.
Harriss E; Bodleian Health Care Libraries, University of Oxford, UK.
Shimakawa Y; Institut Pasteur, Université Paris Cité, Unité d'Épidémiologie des Maladies Émergentes, Paris, France.
Matthews PC; The Francis Crick Institute, 1 Midland Road, London, UK; Department of Infectious Diseases, University College London Hospitals, London, UK; Division of Infection and Immunity, University College London, Gower Street, London, UK.
Pokaż więcej
Źródło:
Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology [J Clin Virol] 2024 Oct; Vol. 174, pp. 105711. Date of Electronic Publication: 2024 Jun 28.
Typ publikacji:
Journal Article; Meta-Analysis; Systematic Review; Research Support, Non-U.S. Gov't
MeSH Terms:
Antiviral Agents*/therapeutic use
Antiviral Agents*/pharmacology
Drug Resistance, Viral*
Guanine*/analogs & derivatives
Guanine*/therapeutic use
Guanine*/pharmacology
Hepatitis B virus*/drug effects
Hepatitis B, Chronic*/drug therapy
Hepatitis B, Chronic*/virology
Tenofovir*/pharmacology
Tenofovir*/therapeutic use
Humans
Czasopismo naukowe
Full Text Finder  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Do Chinese HIV-infected adult patients with altered renal function need to adjust tenofovir disoproxil fumarate dosage? A population pharmacokinetics analysis.
Autorzy:
Chen R; Department of Clinical Research Center, Shanghai Public Health Clinical Center, Fudan University, Jinshan District, Shanghai, 201508, China; Department of Pharmacy, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, 241 Huaihai West Road, Shanghai, 200030, China.
Zhang RF; Department of Clinical Research Center, Shanghai Public Health Clinical Center, Fudan University, Jinshan District, Shanghai, 201508, China.
Xing YR; Department of Clinical Research Center, Shanghai Public Health Clinical Center, Fudan University, Jinshan District, Shanghai, 201508, China; School of Pharmacy, Guilin Medical University, 1 Zhiyuan Road, Lingui District, Guilin 541199, China.
Wang JR; Department of Clinical Research Center, Shanghai Public Health Clinical Center, Fudan University, Jinshan District, Shanghai, 201508, China.
Liu L; Department of Clinical Research Center, Shanghai Public Health Clinical Center, Fudan University, Jinshan District, Shanghai, 201508, China.
Yin L; Department of Clinical Research Center, Shanghai Public Health Clinical Center, Fudan University, Jinshan District, Shanghai, 201508, China.
Li YY; School of Pharmacy, Guilin Medical University, 1 Zhiyuan Road, Lingui District, Guilin 541199, China. Electronic address: .
Jiao Z; Department of Pharmacy, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, 241 Huaihai West Road, Shanghai, 200030, China. Electronic address: .
Zhang LJ; Department of Clinical Research Center, Shanghai Public Health Clinical Center, Fudan University, Jinshan District, Shanghai, 201508, China. Electronic address: .
Pokaż więcej
Źródło:
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences [Eur J Pharm Sci] 2024 Oct 01; Vol. 201, pp. 106851. Date of Electronic Publication: 2024 Jul 14.
Typ publikacji:
Journal Article
MeSH Terms:
Anti-HIV Agents*/pharmacokinetics
Anti-HIV Agents*/administration & dosage
HIV Infections*/drug therapy
Tenofovir*/pharmacokinetics
Tenofovir*/administration & dosage
Adult ; Female ; Humans ; Male ; Middle Aged ; Young Adult ; China ; East Asian People ; Glomerular Filtration Rate ; Models, Biological ; Monte Carlo Method
Czasopismo naukowe
Full Text Finder  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Effects of tenofovir alafenamide fumarate on serum lipid profiles in patients with chronic hepatitis B.
Autorzy:
Cao F; Department of Infectious Diseases, Nanjing Drum Tower Hospital Clinical College of Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, No. 321 Zhongshan Road, Nanjing, Jiangsu, 210008, China.
Fan T; Department of Infectious Diseases, Nanjing Drum Tower Hospital Clinical College of Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, No. 321 Zhongshan Road, Nanjing, Jiangsu, 210008, China.
Jiang X; Department of Clinical Laboratory, Huai'an No. 4 People's Hospital, Huai'an, Jiangsu, China.
Wang J; Department of Infectious Diseases, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, Jiangsu, China.; Institute of Viruses and Infectious Diseases, Nanjing University, Nanjing, Jiangsu, China.
Liu Y; Department of Infectious Diseases, Nanjing Drum Tower Hospital Clinical College of Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, No. 321 Zhongshan Road, Nanjing, Jiangsu, 210008, China.
Zhu L; Department of Infectious Diseases, The Affiliated Infectious Diseases Hospital of Soochow University, Suzhou, Jiangsu, China.
Xiong Y; Department of Infectious Diseases, Nanjing Drum Tower Hospital Clinical College of Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, No. 321 Zhongshan Road, Nanjing, Jiangsu, 210008, China.
Zhang S; Department of Infectious Diseases, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, Jiangsu, China.
Zhang Z; Department of Infectious Diseases, Nanjing Drum Tower Hospital Clinical College of Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, No. 321 Zhongshan Road, Nanjing, Jiangsu, 210008, China.
Pan Y; Department of Infectious Diseases, Nanjing Drum Tower Hospital Clinical College of Nanjing Medical University, Nanjing, Jiangsu, China.
Li Y; Department of Infectious Diseases, Nanjing Drum Tower Hospital Clinical College of Nanjing Medical University, Nanjing, Jiangsu, China.
Jiang C; Department of Infectious Diseases, Nanjing Drum Tower Hospital Clinical College of Jiangsu University, Nanjing, Jiangsu, China.
Xia J; Department of Infectious Diseases, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, Jiangsu, China.
Yan X; Department of Infectious Diseases, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, Jiangsu, China.
Li J; Department of Infectious Diseases, Nanjing Drum Tower Hospital Clinical College of Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, No. 321 Zhongshan Road, Nanjing, Jiangsu, 210008, China.; Department of Infectious Diseases, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, Jiangsu, China.; Institute of Viruses and Infectious Diseases, Nanjing University, Nanjing, Jiangsu, China.
Liu X; Department of Clinical Laboratory, Huai'an No. 4 People's Hospital, Huai'an, Jiangsu, China.
Zhu C; Department of Infectious Diseases, The Affiliated Infectious Diseases Hospital of Soochow University, Suzhou, Jiangsu, China. .
Huang R; Department of Infectious Diseases, Nanjing Drum Tower Hospital Clinical College of Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, No. 321 Zhongshan Road, Nanjing, Jiangsu, 210008, China. doctor_.; Department of Infectious Diseases, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, Jiangsu, China. doctor_.; Institute of Viruses and Infectious Diseases, Nanjing University, Nanjing, Jiangsu, China. doctor_.; Department of Infectious Diseases, Nanjing Drum Tower Hospital Clinical College of Nanjing Medical University, Nanjing, Jiangsu, China. doctor_.; Department of Infectious Diseases, Nanjing Drum Tower Hospital Clinical College of Jiangsu University, Nanjing, Jiangsu, China. doctor_.
Wu C; Department of Infectious Diseases, Nanjing Drum Tower Hospital Clinical College of Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, No. 321 Zhongshan Road, Nanjing, Jiangsu, 210008, China. .; Department of Infectious Diseases, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, Jiangsu, China. .; Institute of Viruses and Infectious Diseases, Nanjing University, Nanjing, Jiangsu, China. .; Department of Infectious Diseases, Nanjing Drum Tower Hospital Clinical College of Nanjing Medical University, Nanjing, Jiangsu, China. .
Pokaż więcej
Źródło:
Virology journal [Virol J] 2024 Sep 28; Vol. 21 (1), pp. 234. Date of Electronic Publication: 2024 Sep 28.
Typ publikacji:
Journal Article; Multicenter Study
MeSH Terms:
Tenofovir*/therapeutic use
Tenofovir*/analogs & derivatives
Hepatitis B, Chronic*/drug therapy
Hepatitis B, Chronic*/blood
Hepatitis B, Chronic*/virology
Antiviral Agents*/therapeutic use
Alanine*/therapeutic use
Lipids*/blood
Humans ; Male ; Female ; Retrospective Studies ; Middle Aged ; Adult ; Dyslipidemias/blood ; Dyslipidemias/drug therapy ; Dyslipidemias/chemically induced ; Adenine/analogs & derivatives ; Adenine/therapeutic use ; Triglycerides/blood ; Cholesterol/blood
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Role of tenofovir dipivoxil in gut microbiota recovery from HBV-infection induced dysbiosis.
Autorzy:
Long J; Department of Pharmacy, Huashan Hospital, Fudan University, Shanghai, China.
Saw M; Department of Pharmacy, Huashan Hospital, Fudan University, Shanghai, China. max_.
Zhang P; Department of Nephrology, Zhongshan Hospital, Fudan University, Shanghai, China. .
Wang L; Department of Pharmacy, Huashan Hospital, Fudan University, Shanghai, China.
Li L; Department of Pharmacy, Jing'an District Central Hospital, Fudan University, Shanghai, China.
Ren H; Shanghai Mobio Biomedical Technology Co., Shanghai, China.
Liu C; Shanghai Mobio Biomedical Technology Co., Shanghai, China.
Ma Z; Department of Infectious Diseases, Shanghai Key Laboratory of Infectious Diseases and Biosafety Emergency Response, National Medical Center for Infectious Diseases, Huashan Hospital, Fudan University, Shanghai, China.
Zhang J; Department of Infectious Diseases, Shanghai Key Laboratory of Infectious Diseases and Biosafety Emergency Response, National Medical Center for Infectious Diseases, Huashan Hospital, Fudan University, Shanghai, China. .; Department of Infectious Diseases, Jing'An Branch of Huashan Hospital, Fudan University, Shanghai, China. .
Wang B; Department of Pharmacy, Huashan Hospital, Fudan University, Shanghai, China. .; Department of Pharmacy, Jing'an District Central Hospital, Fudan University, Shanghai, China. .
Pokaż więcej
Źródło:
BMC microbiology [BMC Microbiol] 2024 Sep 20; Vol. 24 (1), pp. 359. Date of Electronic Publication: 2024 Sep 20.
Typ publikacji:
Journal Article
MeSH Terms:
Dysbiosis*/microbiology
Gastrointestinal Microbiome*/drug effects
Tenofovir*/therapeutic use
Tenofovir*/administration & dosage
Hepatitis B, Chronic*/drug therapy
Hepatitis B, Chronic*/virology
Hepatitis B, Chronic*/microbiology
Antiviral Agents*/therapeutic use
Antiviral Agents*/administration & dosage
Bacteria*/classification
Bacteria*/drug effects
Bacteria*/genetics
Bacteria*/isolation & purification
Feces*/microbiology
Feces*/virology
Humans ; Male ; Female ; Adult ; Middle Aged ; RNA, Ribosomal, 16S/genetics ; Hepatitis B virus/genetics ; Hepatitis B virus/drug effects
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Functional cure induced by tenofovir alafenamide plus peginterferon-alpha-2b in young children with chronic hepatitis B: a case series study.
Autorzy:
Zeng QL; Department of Infectious Diseases and Hepatology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan Province, China. .
Chen RY; Department of Infectious Diseases and Hepatology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan Province, China.
Lv XY; Department of Infectious Diseases and Hepatology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan Province, China.
Huang S; Department of Infectious Diseases and Hepatology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan Province, China.
Li WZ; Department of Infectious Diseases and Hepatology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan Province, China.
Pan YJ; Department of Infectious Diseases and Hepatology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan Province, China.
Wang FS; Treatment and Research Center for Infectious Diseases, The Fifth Medical Center of Chinese PLA General Hospital, National Clinical Research Center for Infectious Diseases, Beijing, China. .
Yu ZJ; Department of Infectious Diseases and Hepatology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan Province, China. .
Pokaż więcej
Źródło:
BMC infectious diseases [BMC Infect Dis] 2024 Aug 15; Vol. 24 (1), pp. 830. Date of Electronic Publication: 2024 Aug 15.
Typ publikacji:
Journal Article
MeSH Terms:
Tenofovir*/therapeutic use
Tenofovir*/administration & dosage
Tenofovir*/analogs & derivatives
Hepatitis B, Chronic*/drug therapy
Hepatitis B, Chronic*/virology
Antiviral Agents*/therapeutic use
Antiviral Agents*/adverse effects
Antiviral Agents*/administration & dosage
Recombinant Proteins*/therapeutic use
Recombinant Proteins*/administration & dosage
Recombinant Proteins*/adverse effects
Polyethylene Glycols*/therapeutic use
Polyethylene Glycols*/adverse effects
Polyethylene Glycols*/administration & dosage
Interferon-alpha*/therapeutic use
Interferon-alpha*/administration & dosage
Interferon-alpha*/adverse effects
Drug Therapy, Combination*
Humans ; Male ; Female ; Child ; Child, Preschool ; Treatment Outcome ; Interferon alpha-2/therapeutic use ; Interferon alpha-2/administration & dosage ; Hepatitis B Surface Antigens/blood ; Hepatitis B e Antigens/blood ; Hepatitis B virus/genetics ; Hepatitis B virus/drug effects ; DNA, Viral/blood ; Alanine/therapeutic use ; Alanine/analogs & derivatives
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Improvement in high-density lipoprotein cholesterol in people with HIV who switched from a tenofovir alafenamide-containing regimen to cabotegravir plus rilpivirine.
Autorzy:
Muccini C; Department of Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy. Electronic address: .
Diotallevi S; Department of Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy.
Lolatto R; Department of Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy.
Piromalli G; Department of Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy.
Spagnuolo V; Department of Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy.
Castagna A; Department of Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy; Vita-Salute San Raffaele University, Milan, Italy.
Pokaż więcej
Źródło:
International journal of antimicrobial agents [Int J Antimicrob Agents] 2024 Oct; Vol. 64 (4), pp. 107312. Date of Electronic Publication: 2024 Aug 29.
Typ publikacji:
Letter
MeSH Terms:
HIV Infections*/drug therapy
Rilpivirine*/therapeutic use
Anti-HIV Agents*/therapeutic use
Pyridones*/therapeutic use
Tenofovir*/therapeutic use
Tenofovir*/analogs & derivatives
Alanine*/therapeutic use
Alanine*/administration & dosage
Humans ; Male ; Middle Aged ; Cholesterol, HDL/blood ; Female ; Pyridines/therapeutic use ; Adenine/analogs & derivatives ; Adenine/therapeutic use ; Adenine/administration & dosage ; Treatment Outcome ; Adult ; Drug Substitution ; Diketopiperazines
Opinia redakcyjna
Full Text Finder  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Osteoporosis in patients with hepatitis B receiving tenofovir disoproxil fumarate: Does fibroblast growth factor 23 play a role?
Autorzy:
van Oorschot E; Department of Gastroenterology, Geriatrics and Internal Medicine (Co-MIK), Zuyderland Medical Centre, Heerlen-Sittard-Geleen, the Netherlands; Department of Internal Medicine, Division of Infectious Diseases, Maastricht University Medical Centre, the Netherlands. Electronic address: .
Koc ÖM; Department of Gastroenterology, Geriatrics and Internal Medicine (Co-MIK), Zuyderland Medical Centre, Heerlen-Sittard-Geleen, the Netherlands; Department of Gastroenterology and Hepatology, Maastricht University Medical Centre, Maastricht, the Netherlands.
Koek GH; Department of Gastroenterology and Hepatology, Maastricht University Medical Centre, Maastricht, the Netherlands.
Pokaż więcej
Źródło:
Journal of hepatology [J Hepatol] 2024 Oct; Vol. 81 (4), pp. e196-e197. Date of Electronic Publication: 2024 May 03.
Typ publikacji:
Letter
MeSH Terms:
Tenofovir*/adverse effects
Tenofovir*/therapeutic use
Fibroblast Growth Factors*/blood
Osteoporosis*/chemically induced
Osteoporosis*/drug therapy
Fibroblast Growth Factor-23*
Humans ; Female ; Antiviral Agents/adverse effects ; Antiviral Agents/therapeutic use ; Hepatitis B/drug therapy ; Male ; Middle Aged ; Hepatitis B, Chronic/drug therapy
Opinia redakcyjna
Full Text Finder  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Protocol of a drug-drug interaction study between bictegravir/emtricitabine/tenofovir alafenamide and feminizing hormones in trans women living with HIV.
Autorzy:
Lacombe-Duncan A; Women's College Hospital, Toronto, Ontario, Canada.; School of Social Work, University of Michigan, Ann Arbor, Michigan, USA.
Tseng A; Toronto General Hospital, Unity Health Network, Toronto, Ontario, Canada.; Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Ontario, Canada.
Scarsi KK; University of Nebraska Medical Center, Omaha, Nebraska, USA.
Senneker T; Kingston Health Sciences Centre, Kingston, Ontario, Canada.
Kluger H; College of Literature, Science, and the Arts, University of Michigan, Ann Arbor, Michigan, USA.
Persad Y; Women's College Hospital, Toronto, Ontario, Canada.
Underhill A; Women's College Hospital, Toronto, Ontario, Canada.
Kennedy VL; Women's College Hospital, Toronto, Ontario, Canada.
Armstrong I; Maple Leaf Medical Clinic, Toronto, Ontario, Canada.
Fung R; Michael Garron Hospital, Toronto, Ontario, Canada.
Bourns A; Sherbourne Health, Toronto, Ontario, Canada.
Nguyen Q; Sherbourne Health, Toronto, Ontario, Canada.; Department of Family and Community Medicine, University of Toronto, Ontario, Canada.
Hranilovic S; St. Michael's Hospital, Toronto, Ontario, Canada.
Weisdorf T; St. Michael's Hospital, Toronto, Ontario, Canada.
Chan L; Department of Family and Community Medicine, University of Toronto, Ontario, Canada.
Kia H; University of British Columbia, Vancouver, British Columbia, Canada.
Halpenny R; Maple Leaf Medical Clinic, Toronto, Ontario, Canada.
Iyer H; Women's College Hospital, Toronto, Ontario, Canada.
Jeyarajah N; Maple Leaf Medical Clinic, Toronto, Ontario, Canada.
Kovchazov G; Maple Leaf Medical Clinic, Toronto, Ontario, Canada.
Tharao W; Women's Health in Women's Hands, Toronto, Ontario, Canada.
Loutfy M; Women's College Hospital, Toronto, Ontario, Canada.; Maple Leaf Medical Clinic, Toronto, Ontario, Canada.; Department of Medicine, University of Toronto, Toronto, Ontario, Canada.
Pokaż więcej
Źródło:
British journal of clinical pharmacology [Br J Clin Pharmacol] 2024 Oct; Vol. 90 (10), pp. 2349-2359. Date of Electronic Publication: 2024 Jul 11.
Typ publikacji:
Journal Article; Clinical Trial Protocol
MeSH Terms:
Drug Interactions*
HIV Infections*/drug therapy
Emtricitabine*/pharmacokinetics
Emtricitabine*/administration & dosage
Tenofovir*/pharmacokinetics
Tenofovir*/administration & dosage
Tenofovir*/analogs & derivatives
Anti-HIV Agents*/pharmacokinetics
Anti-HIV Agents*/administration & dosage
Estradiol*/administration & dosage
Estradiol*/blood
Estradiol*/pharmacokinetics
Piperazines*/administration & dosage
Piperazines*/pharmacokinetics
Transgender Persons*
Adenine*/analogs & derivatives
Adenine*/pharmacokinetics
Adenine*/administration & dosage
Humans ; Female ; Adult ; Heterocyclic Compounds, 4 or More Rings/pharmacokinetics ; Heterocyclic Compounds, 4 or More Rings/administration & dosage ; Alanine/pharmacokinetics ; Alanine/administration & dosage ; Pyridones/administration & dosage ; Pyridones/pharmacokinetics ; Longitudinal Studies ; Drug Combinations ; Androgen Antagonists/pharmacokinetics ; Androgen Antagonists/administration & dosage ; Heterocyclic Compounds, 3-Ring/pharmacokinetics ; Heterocyclic Compounds, 3-Ring/administration & dosage ; Middle Aged ; Young Adult ; Amides/pharmacokinetics ; Amides/administration & dosage
Czasopismo naukowe
Full Text Finder  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Twelve-month effectiveness and safety of bictegravir/emtricitabine/tenofovir alafenamide in treatment-naïve and treatment-experienced people with HIV: Findings from the Asia cohort of the BICSTaR study.
Autorzy:
Tseng YT; Division of Infectious Diseases, Department of Medicine, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan. Electronic address: .
Yang CJ; Department of Internal Medicine, Far Eastern Memorial Hospital, New Taipei City, Taiwan; School of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan. Electronic address: .
Kim YS; Division of Infectious Diseases, Department of Internal Medicine, Chungnam National University School of Medicine, Daejeon, Republic of Korea. Electronic address: .
Choi JY; Division of Infectious Diseases, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea. Electronic address: .
Wong CS; Department of Infectious Diseases, National Centre for Infectious Diseases, Singapore. Electronic address: chen_seong_.
Lee KY; Medical Affairs, Gilead Sciences, Taipei, Taiwan. Electronic address: .
Lee JA; Medical Affairs, Gilead Sciences Korea Ltd, Seoul, Republic of Korea. Electronic address: .
Chang J; Medical Affairs, Gilead Sciences, Taipei, Taiwan. Electronic address: .
Harrison R; Real World Evidence, Gilead Sciences Europe Ltd, Uxbridge, United Kingdom. Electronic address: .
Marongiu A; Real World Evidence, Gilead Sciences Europe Ltd, Uxbridge, United Kingdom. Electronic address: .
Lee SH; Department of Internal Medicine, Pusan National University School of Medicine and Pusan National University Hospital, Busan, Republic of Korea. Electronic address: .
Hung CC; Department of Internal Medicine, National Taiwan University Hospital Yunlin Branch, Yunlin, Taiwan; Department of Tropical Medicine and Parasitology, National Taiwan University College of Medicine, Taipei, Taiwan; Department of Internal Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan. Electronic address: .
Pokaż więcej
Źródło:
Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi [J Microbiol Immunol Infect] 2024 Oct; Vol. 57 (5), pp. 760-770. Date of Electronic Publication: 2024 Jul 14.
Typ publikacji:
Journal Article; Observational Study
MeSH Terms:
HIV Infections*/drug therapy
HIV Infections*/virology
Tenofovir*/therapeutic use
Tenofovir*/analogs & derivatives
Emtricitabine*/therapeutic use
Anti-HIV Agents*/therapeutic use
Anti-HIV Agents*/adverse effects
Pyridones*/therapeutic use
HIV-1*/drug effects
HIV-1*/genetics
Humans ; Male ; Female ; Adult ; Retrospective Studies ; Middle Aged ; Prospective Studies ; Treatment Outcome ; CD4 Lymphocyte Count ; Heterocyclic Compounds, 4 or More Rings/therapeutic use ; Heterocyclic Compounds, 4 or More Rings/adverse effects ; Piperazines/therapeutic use ; Adenine/analogs & derivatives ; Adenine/therapeutic use ; Adenine/adverse effects ; Alanine/therapeutic use ; Alanine/analogs & derivatives ; Drug Combinations ; Viral Load/drug effects ; Heterocyclic Compounds, 3-Ring/therapeutic use ; Heterocyclic Compounds, 3-Ring/adverse effects ; Singapore/epidemiology ; Amides/therapeutic use ; Taiwan ; Cohort Studies ; RNA, Viral/blood
Czasopismo naukowe
Full Text Finder  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Does long-term use of tenofovir disoproxil fumarate affect fracture risk in patients with chronic hepatitis B?
Autorzy:
Zhang H; Longhua Hospital Shanghai University of Traditional Chinese Medicine, Shanghai 200032, China.
Huang J; Longhua Hospital Shanghai University of Traditional Chinese Medicine, Shanghai 200032, China; Gansu Provincial Hospital of Traditional Chinese Medicine, Lanzhou 730050, Gansu, China.
Zhu W; Longhua Hospital Shanghai University of Traditional Chinese Medicine, Shanghai 200032, China.
Feng W; The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou 510405, Guangdong, China. Electronic address: .
Zeng Y; The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou 510405, Guangdong, China. Electronic address: .
Pokaż więcej
Źródło:
Journal of hepatology [J Hepatol] 2024 Oct; Vol. 81 (4), pp. e199-e200. Date of Electronic Publication: 2024 Jun 13.
Typ publikacji:
Letter
MeSH Terms:
Tenofovir*/adverse effects
Tenofovir*/administration & dosage
Hepatitis B, Chronic*/drug therapy
Hepatitis B, Chronic*/complications
Fractures, Bone*/epidemiology
Fractures, Bone*/chemically induced
Fractures, Bone*/etiology
Fractures, Bone*/prevention & control
Antiviral Agents*/adverse effects
Humans ; Male ; Female ; Middle Aged ; Adult
Opinia redakcyjna
Full Text Finder  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Enhancing the understanding of the risk of incident fracture in entecavir- and TDF-treated elderly patients with chronic hepatitis B.
Autorzy:
Wen Z; Department of Pharmacy, Heyuan People's Hospital, Heyuan, China. Electronic address: .
Pokaż więcej
Źródło:
Journal of hepatology [J Hepatol] 2024 Oct; Vol. 81 (4), pp. e198. Date of Electronic Publication: 2024 May 16.
Typ publikacji:
Letter
MeSH Terms:
Hepatitis B, Chronic*/drug therapy
Hepatitis B, Chronic*/epidemiology
Hepatitis B, Chronic*/complications
Guanine*/analogs & derivatives
Guanine*/therapeutic use
Guanine*/adverse effects
Antiviral Agents*/adverse effects
Antiviral Agents*/therapeutic use
Tenofovir*/adverse effects
Tenofovir*/therapeutic use
Humans ; Aged ; Fractures, Bone/epidemiology ; Fractures, Bone/etiology ; Male ; Female ; Incidence ; Risk Factors ; Aged, 80 and over
Opinia redakcyjna
Full Text Finder  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Viral load suppression and HIV-1 drug resistance mutations in persons with HIV on TLD/TAFED in Zambia.
Autorzy:
Luwaya EL; School of Medicine and Health Sciences, Mulungushi University, Livingstone, Zambia.
Mwape L; School of Medicine and Health Sciences, Mulungushi University, Livingstone, Zambia.
Bwalya K; School of Medicine and Health Sciences, Mulungushi University, Livingstone, Zambia.
Siakabanze C; School of Medicine and Health Sciences, Mulungushi University, Livingstone, Zambia.
Hamooya BM; School of Medicine and Health Sciences, Mulungushi University, Livingstone, Zambia.
Masenga SK; School of Medicine and Health Sciences, Mulungushi University, Livingstone, Zambia.; Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, United States of America.
Pokaż więcej
Źródło:
PloS one [PLoS One] 2024 Sep 06; Vol. 19 (9), pp. e0308869. Date of Electronic Publication: 2024 Sep 06 (Print Publication: 2024).
Typ publikacji:
Journal Article
MeSH Terms:
HIV-1*/genetics
HIV-1*/drug effects
HIV Infections*/drug therapy
HIV Infections*/virology
Drug Resistance, Viral*/genetics
Viral Load*/drug effects
Mutation*
Tenofovir*/therapeutic use
Tenofovir*/pharmacology
Anti-HIV Agents*/therapeutic use
Anti-HIV Agents*/pharmacology
Piperazines*/therapeutic use
Lamivudine*/therapeutic use
Lamivudine*/pharmacology
Pyridones*/therapeutic use
Humans ; Female ; Adult ; Male ; Zambia/epidemiology ; Cross-Sectional Studies ; Oxazines/therapeutic use ; Heterocyclic Compounds, 3-Ring/therapeutic use ; Heterocyclic Compounds, 3-Ring/pharmacology ; Emtricitabine/therapeutic use ; Middle Aged ; Young Adult ; Adolescent ; Drug Combinations
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Comparing pill counts and patient self-reports versus DBS tenofovir concentrations as ART adherence measurements with virologic outcomes and HIV drug resistance in a cohort of adolescents and young adults failing ART in Harare, Zimbabwe.
Autorzy:
Mtisi TJ; Internal Medicine Unit, Department of Primary Healthcare Sciences, University of Zimbabwe, Harare, Zimbabwe.
Kouamou V; Internal Medicine Unit, Department of Primary Healthcare Sciences, University of Zimbabwe, Harare, Zimbabwe.
Morse GD; Translational Pharmacology Research Core, State University of New York at Buffalo, NY14203, USA.
Dzinamarira T; ICAP at Columbia University, Harare, Zimbabwe; School of Health Systems and Public Health, University of Pretoria, Pretoria, South Africa. Electronic address: .
Ndhlovu CE; Internal Medicine Unit, Department of Primary Healthcare Sciences, University of Zimbabwe, Harare, Zimbabwe.
Pokaż więcej
Źródło:
Journal of infection and public health [J Infect Public Health] 2024 Sep; Vol. 17 (9), pp. 102500. Date of Electronic Publication: 2024 Jul 17.
Typ publikacji:
Clinical Study; Comparative Study; Journal Article
MeSH Terms:
Anti-HIV Agents*/therapeutic use
HIV Infections*/drug therapy
Medication Adherence*/statistics & numerical data
Self Report*
Tenofovir*/therapeutic use
Viral Load*/drug effects
Adolescent ; Adult ; Child ; Female ; Humans ; Male ; Young Adult ; Chromatography, Liquid/methods ; Cohort Studies ; Dried Blood Spot Testing/methods ; Drug Resistance, Viral ; Tandem Mass Spectrometry/methods ; Treatment Failure ; Zimbabwe
Czasopismo naukowe
Full Text Finder  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Determination of intracellular tenofovir-diphosphate and emtricitabine-triphosphate concentrations in dried blood spots for pre-exposure prophylaxis adherence.
Autorzy:
Tsuchiya K; AIDS Clinical Center, National Center for Global Health and Medicine, Tokyo, Japan. Electronic address: .
Hayashi Y; Division of Molecular Pharmacology, National Cancer Center Research Institute, Tokyo, Japan; CMIC Pharma Science, Yamanashi, Japan.
Ryu S; Division of Molecular Pharmacology, National Cancer Center Research Institute, Tokyo, Japan.
Tran HT; AIDS Clinical Center, National Center for Global Health and Medicine, Tokyo, Japan; Joint Research Center for Human Retrovirus Infection, Kumamoto University, Kumamoto, Japan.
Takano M; AIDS Clinical Center, National Center for Global Health and Medicine, Tokyo, Japan.
Tanaka K; AIDS Clinical Center, National Center for Global Health and Medicine, Tokyo, Japan.
Mizushima D; AIDS Clinical Center, National Center for Global Health and Medicine, Tokyo, Japan.
Oka S; AIDS Clinical Center, National Center for Global Health and Medicine, Tokyo, Japan; Joint Research Center for Human Retrovirus Infection, Kumamoto University, Kumamoto, Japan.
Gatanaga H; AIDS Clinical Center, National Center for Global Health and Medicine, Tokyo, Japan; Joint Research Center for Human Retrovirus Infection, Kumamoto University, Kumamoto, Japan.
Hamada A; Division of Molecular Pharmacology, National Cancer Center Research Institute, Tokyo, Japan.
Pokaż więcej
Źródło:
Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy [J Infect Chemother] 2024 Sep; Vol. 30 (9), pp. 876-880. Date of Electronic Publication: 2024 Mar 01.
Typ publikacji:
Journal Article
MeSH Terms:
Emtricitabine*/pharmacokinetics
Emtricitabine*/administration & dosage
Emtricitabine*/blood
Pre-Exposure Prophylaxis*/methods
HIV Infections*/prevention & control
Dried Blood Spot Testing*/methods
Tandem Mass Spectrometry*/methods
Anti-HIV Agents*/blood
Anti-HIV Agents*/pharmacokinetics
Anti-HIV Agents*/administration & dosage
Tenofovir*/blood
Tenofovir*/pharmacokinetics
Tenofovir*/administration & dosage
Humans ; Male ; Female ; Adult ; Chromatography, Liquid/methods ; Middle Aged ; Adenine/analogs & derivatives ; Adenine/administration & dosage ; Adenine/pharmacokinetics ; Adenine/blood ; Adenine/therapeutic use ; Medication Adherence ; Organophosphates/blood ; Organophosphates/pharmacokinetics ; Organophosphates/administration & dosage ; Organophosphates/analysis ; Polyphosphates/analysis ; Polyphosphates/blood
Czasopismo naukowe
Full Text Finder  Link otwiera się w nowym oknieSzczegóły
Tytuł:
A systematic review and meta-analysis of maternal weight changes and pregnancy outcomes associated with integrase inhibitors and tenofovir alafenamide in pregnant women with HIV.
Autorzy:
Eke AC; Division of Maternal-Fetal Medicine, Department of Gynecology and Obstetrics, Johns Hopkins University School of Medicine, Baltimore, MD. Electronic address: .
Ramaiyer M; Johns Hopkins University School of Medicine, Baltimore, MD.
Eleje GU; Department of Obstetrics and Gynecology, Nnamdi Azikiwe University Teaching Hospital, Nnewi, Nigeria.
Ezebialu IU; Department of Obstetrics and Gynecology, Chukwuemeka Odumegwu Ojukwu University Teaching Hospital, Awka, Nigeria.
Aliyu MH; Vanderbilt Institute for Global Health, Vanderbilt University Medical Center, Nashville, TN.
Pokaż więcej
Źródło:
American journal of obstetrics & gynecology MFM [Am J Obstet Gynecol MFM] 2024 Aug; Vol. 6 (8), pp. 101406. Date of Electronic Publication: 2024 Jun 10.
Typ publikacji:
Journal Article; Meta-Analysis; Systematic Review
MeSH Terms:
Alanine*/administration & dosage
Alanine*/adverse effects
Alanine*/analogs & derivatives
HIV Infections*/drug therapy
HIV Integrase Inhibitors*/administration & dosage
HIV Integrase Inhibitors*/adverse effects
HIV Integrase Inhibitors*/pharmacology
Pregnancy Complications, Infectious*/drug therapy
Pregnancy Complications, Infectious*/virology
Pregnancy Outcome*/epidemiology
Tenofovir*/administration & dosage
Tenofovir*/adverse effects
Tenofovir*/analogs & derivatives
Female ; Humans ; Pregnancy ; Adenine/administration & dosage ; Adenine/adverse effects ; Adenine/analogs & derivatives ; Anti-HIV Agents/administration & dosage ; Anti-HIV Agents/adverse effects ; Body Weight/drug effects
Czasopismo naukowe
Full Text Finder  Link otwiera się w nowym oknieSzczegóły
Wyświetlanie 1-20 z 13372

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies